Recent Price Moves Put Amphastar Pharmaceuticals in Focus
Amphastar Pharmaceuticals (AMPH) has drawn fresh attention after recent share price swings, with the stock closing at $23.18 and showing mixed performance over the past week, month, past 3 months, and year.
Short term, Amphastar Pharmaceuticals has seen momentum build, with a 30-day share price return of 11.55% and a 90-day share price return of 19.55%. Yet the 1-year total shareholder return is down 21.21%, pointing to a recovery that is still being reassessed by the market in light of perceived growth prospects and risk.
Spot opportunities with similar recovery stories to Amphastar Pharmaceuticals by reviewing the hand picked 47 high quality undervalued stocks, which combine solid fundamentals with recent share price pressure.
For Amphastar Pharmaceuticals, the recent rebound after a weaker year could point to growing confidence in the underlying business, or simply a shift in sentiment after heavy selling. Which story does the current valuation tell?
Most Popular Narrative: 1.5% Overvalued
The most followed narrative for Amphastar Pharmaceuticals puts fair value at $22.83, slightly below the latest close at $23.18, and sets out a detailed earnings reset story.
The analysts have a consensus price target of $22.83 for Amphastar Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $30.0, and the most bearish reporting a price target of just $19.0.
Read the complete narrative. Read the complete narrative.
The fair value narrative is based on modest revenue growth, thinner margins, and a different profit multiple several years from now. Want to see exactly how those moving parts are combined into a single valuation story and which assumptions carry the most weight for Amphastar Pharmaceuticals?
Result: Fair Value of $22.83 (OVERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, if Amphastar Pharmaceuticals executes on its expanded U.S. manufacturing plans and key pipeline assets like AMP-004 progress well, this reset narrative could shift quickly.
Find out about the key risks to this Amphastar Pharmaceuticals narrative.
Another View on Amphastar Pharmaceuticals Valuation
While the analyst narrative suggests Amphastar Pharmaceuticals is about 1.5% overvalued at a fair value of $22.83, the current P/E ratio of 12.6x tells a different story. It sits well below the US Pharmaceuticals industry average of 16.2x and below a fair ratio of 14.5x, which implies the market could shift toward a higher earnings multiple over time. That gap can mean mispricing risk or opportunity depending on how you see Amphastar Pharmaceuticals’ earnings outlook and balance sheet.
